Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1)

[Edit]

GPATC7; GPATCH7; VG5Q; Angiogenic factor VG5Q; G patch domain-containing protein 7; Vasculogenesis gene on 5q protein

Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1)
The AGGF1 gene encodes a potent angiogenic factor that contains a forkhead-associated domain and a G-patch domain. VG5Q was ubiquitously expressed in human tissues examined, including heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas. Intracellular localization studies showed VG5Q protein mostly in the cytoplasm and around the nuclei of HMVECs. In an in vitro model of angiogenesis where endothelial cells were plated onto matrigel, VG5Q protein began to redistribute by moving towards the cell periphery and was also detected outside the cell. Purified wildtype VG5Q protein promoted strong angiogenesis in a chick chorioallantoic membrane assay, demonstrating that VG5Q is a potent angiogenic factor. Angiogenesis was inhibited by RNA interference against VG5Q in in vitro assays.

Organism species: Homo sapiens (Human)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPL178Hu01 Recombinant Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) Positive Control; Immunogen; SDS-PAGE; WB.
RPL178Hu02 Recombinant Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) Positive Control; Immunogen; SDS-PAGE; WB.
Antibodies PAL178Hu01 Polyclonal Antibody to Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) WB; IHC; ICC; IP.
LAL178Hu71 Biotin-Linked Polyclonal Antibody to Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) WB; IHC; ICC.
MAL178Hu21 Monoclonal Antibody to Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) WB; IHC; ICC; IP.
PAL178Hu02 Polyclonal Antibody to Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) WB; IHC; ICC; IP.
Assay Kits SEL178Hu ELISA Kit for Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) Enzyme-linked immunosorbent assay for Antigen Detection.

Organism species: Mus musculus (Mouse)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPL178Mu01 Recombinant Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) Positive Control; Immunogen; SDS-PAGE; WB.
RPL178Mu02 Recombinant Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) Positive Control; Immunogen; SDS-PAGE; WB.
Antibodies PAL178Mu01 Polyclonal Antibody to Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) WB; IHC; ICC; IP.
PAL178Mu02 Polyclonal Antibody to Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) WB; IHC; ICC; IP.
Assay Kits SEL178Mu ELISA Kit for Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) Enzyme-linked immunosorbent assay for Antigen Detection.

Organism species: Rattus norvegicus (Rat)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPL178Ra01 Recombinant Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) Positive Control; Immunogen; SDS-PAGE; WB.
Antibodies MAL178Ra21 Monoclonal Antibody to Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) WB; IHC; ICC; IP.
PAL178Ra01 Polyclonal Antibody to Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) WB; IHC; ICC; IP.
Assay Kits SEL178Ra ELISA Kit for Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) Enzyme-linked immunosorbent assay for Antigen Detection.
  1. "Identification of an angiogenic factor that when mutated causes susceptibility to Klippel-Trenaunay syndrome."Nature 427:640-645(2004) [PubMed] [Europe PMC] [Abstract]
  2. "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]
  3. "Complete sequencing and characterization of 21,243 full-length human cDNAs." Nat. Genet. 36:40-45(2004) [PubMed] [Europe PMC] [Abstract]
  4. "Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach."Anal. Chem. 81:4493-4501(2009) [PubMed] [Europe PMC] [Abstract]
  5. "Lysine acetylation targets protein complexes and co-regulates major cellular functions."Science 325:834-840(2009) [PubMed] [Europe PMC] [Abstract]